Pathogenic role of IL-17 in psoriasis and psoriatic arthritis |
| |
| Institution: | 1. Unidad de Dermatología, Departamento de Clínica Médica, Facultad de Medicina de Ribeirão Preto, Universidad de São Paulo, São Paulo, Brasil;2. Unidad de Dermatología, Departamento de Clínica Médica, Universidad de Brasilia, Distrito Federal, Brasil;1. Department of Dermatology, Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, Barcelona, España;2. Department of Dermatology, Hospital Universitari Germans Trias i Pujol, Universitat Autònoma de Barcelona, Barcelona, España;1. Servicio de Dermatología, Hospital General Universitario de Ciudad Real, Ciudad Real, España;2. Servicio de Anatomía Patológica, Hospital General Universitario de Ciudad Real, Ciudad Real, España |
| |
| Abstract: | Psoriasis is a chronic inflammatory skin disorder resulting from a complex network of cytokines and chemokines produced by various immune cell types and tissue cells. Emerging evidence suggests a central role of IL-17 and IL-23/T17 axis in the pathogenesis of psoriasis, giving a rationale for using IL-17-blocking agents as therapeutics.Three agents targeting IL-17 signaling are being studied in Phase III clinical trials: secukinumab and ixekizumab (IL-17 neutralizing agents), and brodalumab (IL-17 receptor antagonist). Preliminary results are highly promising for all anti-IL17 agents, creating fair expectations on this class of agents as the new effective therapeutic approach for the treatment of psoriasis. |
| |
| Keywords: | IL-17 Psoriasis Arthritis Secukinumab Ixekizumab Brodalumab Atherosclerosis Obesity IL-17 Psoriasis Artritis Secukinumab Ixekizumab Brodalumab Aterosclerosis Obesidad |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
